Game Changing FDA Approval for Cancer Immunotherapy Lifileucel After 40 Years: Amtagvi Receives Accelerated FDA Approval for Advanced Melanoma
LOS ANGELES, California – After nearly four decades since its inception, the first TIL therapy has received accelerated approval from the Food and Drug Administration for advanced melanoma. This immunotherapy, which harvests cancer-fighting immune cells from the patient’s own body, is called Amtagvi or lifileucel from Iovance, and is the first cell therapy approved for a solid tumor. Allison Betof Warner, a cell therapy researcher and physician at Stanford University, expressed her excitement and gratification, …